Literature DB >> 23610237

Venous thromboembolism in elderly high-risk medical patients: time course of events and influence of risk factors.

Russell D Hull1, Tazmin Merali, Allan Mills, Abigail L Stevenson, Jane Liang.   

Abstract

Venous thromboembolism (VTE) causes significant morbidity and mortality in hospitalized medical populations; however, medical patients do not currently receive thromboprophylaxis beyond their hospital stay. We reviewed the real-life occurrence of VTE-related care for 100 days post-hospitalization in Calgary, Canada. Using medical visit records with a unique patient identifier number applied throughout the city's hospitals, 989 high-risk patients were selected for review. Almost three-quarters of the elderly patients received appropriate prophylaxis while in hospital, and only 2% received prophylaxis on discharge. Over the 100-day follow-up, 21% of the patients presented with clinically suspected VTE, of which 3.8% had confirmed VTE. Patients with multiple risk factors (≥ 3) had the highest frequency of confirmed VTE (≥ 6.1%). This study suggests that the actual rate of VTE-related follow-up care in patients post-hospitalization is high in the first 100 days, particularly among those who have multiple risk factors, warranting consideration of extended thromboprophylaxis in this population.

Entities:  

Keywords:  anticoagulants; deep venous thrombosis; pulmonary embolism; thrombosis; thrombosis prophylaxis; venous thromboembolism

Mesh:

Substances:

Year:  2013        PMID: 23610237     DOI: 10.1177/1076029613481105

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  15 in total

1.  Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients?

Authors:  Franco Piovella; Diana Irina Iosub
Journal:  Intern Emerg Med       Date:  2018-09-27       Impact factor: 3.397

Review 2.  Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes.

Authors:  Walter Ageno
Journal:  Intern Emerg Med       Date:  2017-08-14       Impact factor: 3.397

Review 3.  Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Aaron Y L Liew; Siavash Piran; John W Eikelboom; James D Douketis
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

Review 4.  Challenges of extended venous thromboembolism prophylaxis in medical and surgical patients.

Authors:  Maria Chiara Chindamo; Edison Ferreira Paiva; Plinio Resende do Carmo; Ana Thereza Cavalcanti Rocha; Marcos Arêas Marques
Journal:  J Vasc Bras       Date:  2022-06-27

5.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

6.  Venous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study.

Authors:  Ximena Jordan Bruno; Insu Koh; Pamela L Lutsey; Robert F Walker; Nicholas S Roetker; Katherine Wilkinson; Nicolas L Smith; Timothy B Plante; Allen B Repp; Chris E Holmes; Mary Cushman; Neil A Zakai
Journal:  J Thromb Haemost       Date:  2022-04-27       Impact factor: 16.036

7.  Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.

Authors:  Alex C Spyropoulos; Concetta Lipardi; Jianfeng Xu; Wentao Lu; Eunyoung Suh; Zhong Yuan; Bennett Levitan; Chiara Sugarmann; Yoriko De Sanctis; Theodore E Spiro; Elliot S Barnathan; Gary E Raskob
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

8.  Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.

Authors:  Walter Ageno; Renato D Lopes; Mark Goldin; Roger D Yusen; Gregory W Albers; Gregory C Elliott; Jonathan L Halperin; William R Hiatt; Gregory Maynard; Philippe Gabriel Steg; Jeffrey I Weitz; Eunyoung Suh; Wentao Lu; Elliot S Barnathan; Gary E Raskob; Alex C Spyropoulos
Journal:  J Thromb Haemost       Date:  2021-08-17       Impact factor: 16.036

Review 9.  Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients.

Authors:  Benjamin Brenner; Roopen Arya; Jan Beyer-Westendorf; James Douketis; Russell Hull; Ismail Elalamy; Davide Imberti; Zhenguo Zhai
Journal:  Thromb J       Date:  2019-12-27

10.  Post-discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers.

Authors:  Scott C Woller; Scott M Stevens; Masarret Fazili; James F Lloyd; Emily L Wilson; Gregory L Snow; Joseph R Bledsoe; Benjamin D Horne
Journal:  Res Pract Thromb Haemost       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.